These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6295890)

  • 41. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
    Altundag K; Bulut N; Sari E; Harputluoglu H
    Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
    [No Abstract]   [Full Text] [Related]  

  • 42. Malignant and benign human mammary disease: estrogen binding in relation to clinical data.
    Terenius L; Johansson H; Rimsten A; Thorén L
    Cancer; 1974 May; 33(5):1364-8. PubMed ID: 4362956
    [No Abstract]   [Full Text] [Related]  

  • 43. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer?
    Paredes J; Milanezi F; Reis-Filho JS; Leitão D; Athanazio D; Schmitt F
    Pathol Res Pract; 2002; 198(12):795-801. PubMed ID: 12608656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of two score systems in Bcl-2 and Bax protein expression in invasive ductal carcinoma of breast and relation with oestrogen and progestrone receptors.
    Ayatollahi H; Ghaffarzadegan K; Sharifi N; Farahmand MJ; Jarafian AH
    Breast J; 2009; 15(3):310-2. PubMed ID: 19645793
    [No Abstract]   [Full Text] [Related]  

  • 45. Tissue binding of lectins in disorders of the breast.
    Franklin WA
    Cancer; 1983 Jan; 51(2):295-300. PubMed ID: 6295598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
    MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
    Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estrogen receptor characterization in a transplantable mouse mammary tumor.
    Watson C; Medina D; Clark JH
    Cancer Res; 1977 Sep; 37(9):3344-8. PubMed ID: 195726
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparison between histologic type, estrogen receptor, and nuclear DNA content in mammary carcinoma.
    Erhardt K; Auer G; Folin A; Silfverswärd C; Skoog L
    Am J Clin Oncol; 1986 Feb; 9(1):83-9. PubMed ID: 3006475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the microTICAS image analysis system.
    Franklin WA; Bibbo M; Doria MI; Dytch HE; Toth J; DeSombre E; Wied GL
    Anal Quant Cytol Histol; 1987 Aug; 9(4):279-86. PubMed ID: 2822057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
    Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
    Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
    [No Abstract]   [Full Text] [Related]  

  • 52. The histopathological evaluation of human breast cancers in correlation with estrogen receptor values.
    Parl FF; Wagner RK
    Cancer; 1980 Jul; 46(2):362-7. PubMed ID: 6248193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
    Tran DD; Lawson JS
    Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer.
    Panahi M; Saki N; Ashourzadeh S; Rahim F
    Asian Pac J Cancer Prev; 2013; 14(6):3699-703. PubMed ID: 23886168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors.
    Hanby AM; McKee P; Jeffery M; Grayson W; Dublin E; Poulsom R; Maguire B
    Am J Surg Pathol; 1998 Sep; 22(9):1125-31. PubMed ID: 9737246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hormone receptor status in breast cancer in comparison with histologic tumor type].
    Kasch R; Meissner J; Haack D; Neumann S
    Zentralbl Gynakol; 1987; 109(24):1493-6. PubMed ID: 2831683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
    Lüttges J; Zamboni G; Longnecker D; Klöppel G
    Am J Surg Pathol; 2001 Jul; 25(7):942-8. PubMed ID: 11420467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The many faces of triple negative breast cancer.
    Comănescu M; Potecă A; Cocosila C; Potecă T
    Chirurgia (Bucur); 2014; 109(4):471-9. PubMed ID: 25149609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of estrogen receptor protein and histopathologic characteristics in 175 cases of breast carcinoma.
    Ahluwali CK; Verma U; Sundaram KR; Verma K
    Indian J Pathol Microbiol; 1987 Jul; 30(3):299-305. PubMed ID: 2835317
    [No Abstract]   [Full Text] [Related]  

  • 60. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
    AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
    Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.